Reviews/Motor Neurone Disease Treatment/Multidisciplinary care prolongs survival
Care · MND-CARE-02 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Across several real-world patient populations, people with ALS who were cared for in a multidisciplinary clinic tended to live longer than those seen in general neurology [1][2][6]. The same pattern did not appear in one Italian population study, where survival was essentially identical in both groups [3]. A core problem is that patients in the clinics were not comparable to the others: in one study they were about five years younger and far more likely to be taking riluzole, a drug that itself extends survival [1]. None of these studies randomly assigned patients to a clinic, so healthier or better-supported patients may simply have ended up in the clinics. The benefit also tended to concentrate in spinal-onset patients and was weak or absent in bulbar-onset disease [3][6]. The panel treated the association as real and repeated, but not strong enough proof that the clinic itself causes longer survival.
Three population or cohort studies from Ireland, Northern Ireland and Austria report longer survival for patients attending multidisciplinary or specialised clinics, with the clinic remaining an independent predictor after multivariate adjustment in [1] (HR=1.47, p=0.02) and [2] (HR 0.59, 95% CI 0.49 to 0.71, p<0.001) [6]. In [1] the median survival advantage was 7.5 months (p<0.0001), and in [6] median survival was 40.0 months versus 27.0 months (p=0.0173). One population-based study found no difference (17.6 versus 18 months; HR 0.91, 95% CI 0.44-1.89, p=0.9) [3]. The benefit was concentrated in spinal-onset patients and attenuated or absent in bulbar onset in both [3] and [6]. Every included study is observational, with no randomised comparison present in the corpus. The contested point: The evidence divides on whether the survival association reflects the clinic itself or the patients who reach it: in [1] the clinic cohort was five years younger (60.1 v 65.6) and far more likely to receive riluzole (99% v 61%), both of which independently affect survival. The division is sharpest between the positive adjusted associations in [1], [2] and [6] and the flatly negative population result in [3], which concludes multidisciplinary care does not improve survival.
All 7 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Motor Neurone Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Confounding by indication: in [1] the MDC cohort was ~5 years younger (60.1 vs 65.6) and had riluzole use of 99% vs 61%; riluzole independently prolongs survival, so the survival effect attributed to the clinic is partly a drug and age effect that multivariate adjustment cannot fully remove.
Causal overreach: the claim states MDC care 'prolongs' survival, a causal assertion, but every included study is observational with no randomised comparison in the corpus; selection of healthier, better-supported patients into MDCs is unaddressed.
Where it remains uncertain. One population-based study found no survival difference (17.6 v 18 months; HR 0.91, p=0.9) [3], and the positive studies feature large baseline imbalances in age and riluzole use that adjustment cannot fully remove [1].
Aleatory
The negative study [3] rests on 126 patients with a wide confidence interval (HR 0.91, 95% CI 0.44-1.89), so chance variation cannot be ruled out as the reason it diverges from the positive studies.
Epistemic
In [1] the clinic cohort was five years younger (60.1 v 65.6) and used riluzole at 99% v 61%; healthier, better-supported patients may preferentially reach clinics, and the corpus does not measure who was steered where.
The load-bearing papers from a corpus of 7, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary positive signal: MDC attendance independently associated with survival; median 7.5 months longer.
“Using multivariate analysis, attendance at the ALS clinic was an independent covariate of survival (HR = 1.47, p = 0.02).”
Panel auditInternal validity: low · scope of inference: Population-based ALS cases in Ireland 1996-2000 comparing clinic type.Key limitations: observational, non-randomised · clinic cohort younger · much higher riluzole use in clinic cohort · self-selection into clinic
Larger population-based cohort confirming a survival advantage for MDC attendance, preserved after multivariate analysis.
“A survival benefit was identified for patients who attended the multidisciplinary ALS clinic in the RoI. (HR 0.59, 95% CI 0.49 to 0.71, p<0.001).”
Panel auditInternal validity: medium · scope of inference: Population-based ALS cases in Republic of Ireland and Northern Ireland, 2005-2010.Key limitations: observational, non-randomised · self-selection into clinic · cross-jurisdiction comparison
Contradicting population-based evidence: no survival benefit, tempering the consistency of the positive studies.
“No difference in median survival time from the diagnosis was observed between patients followed by ALS multidisciplinary (17.6 months) and general clinics (18 months).”
Panel auditInternal validity: medium · scope of inference: Population-based ALS cases in Puglia, Southern Italy, diagnosed 1998-99.Key limitations: small sample · observational · limited statistical power · wide confidence interval (HR 0.91, 95%CI 0.44-1.89)
3 of 7 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Replicated, adjusted survival associations across independent populations support the claim at Likely, held below Established by uniformly observational designs, severe confounding, and one contradicting negative study.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomised comparison of clinic versus general care. Every included study is observational [1][2][3][6]; the causal word 'prolongs' cannot be tested against selection and confounding without a comparison that balances prognosis by design. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A pragmatic cluster-randomised or stepped-wedge trial assigning newly diagnosed ALS patients to multidisciplinary clinic versus general neurology care with survival as the primary endpoint.
Open question: Does multidisciplinary clinic care prolong survival when patients are allocated by design rather than by referral pattern? Why it is still open: The corpus contains only observational studies [1][2][3][6] with no randomised comparison, so selection into clinics is unaddressed.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19